USD 32 million (approx. KRW 43 billion) technology transfer agreement signed with Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Japan’s Astellas Pharma
Early conclusion of Phase 1/2a clinical trial for hESC-RPE (embryonic) therapy for age-related macular degeneration
Matica Biotechnology unveils proprietary cell line “MatiMax.”
CHA General Research Institute signs a joint R&D agreement with JINCORE for gene therapy targeting rare blood disorders
Safety and tolerability confirmed in Phase 1/2a clinical trial for CordSTEM®-DD, a cell therapy for chronic lower back pain caused by degenerative lumbar disc
Winner of the “2023 Korea Pharmaceutical & Bio Industry Award” from Korea Economic TV
Material transfer agreement signed with Centenaire Biosciences for NK cell therapy combination therapies
Introduction of viral vectors and cell lines for CAR-NK cell therapy development
CDMO contract with FromBio for alopecia cell therapy

2022

IND approval for Phase 1 clinical trial of CordSTEM®-POI for premature ovarian insufficiency
Safety and tolerability confirmed in Phase 1 clinical trial for CBT101, an immune cell therapy for solid tumors
Completion of Phase 2a dosing in CordSTEM®-DD clinical trial for chronic lower back pain due to degenerative lumbar disc.

2021

Completion of Phase 1 clinical trial for CBT101, an immune cell therapy for solid tumors
Selection of three projects under the “Pan-Ministerial Regenerative Medicine Technology Development Program.”
First Korean entry into the Australian genome analysis market
First patient dosed in Phase 2a clinical trial for CordSTEM®-DD for chronic lower back pain
Matica BioLabs (formerly CHA Bio Lab) becomes the first company in Korea to obtain all three licenses under the Advanced Regenerative Bio Act
Completion of Phase 1 clinical trial for CordSTEM®-DD
CDMO contract signed with SCM Lifescience
Comprehensive joint research agreement signed with Texas A&M University by Matica Biotechnology

2020

IND approval for CordSTEM®-DD Phase 1/2a clinical trial for chronic lower back pain due to degenerative lumbar disc
IND approval for CBT101 Phase 1 clinical trial for solid tumors in Korea
U.S. FDA orphan drug designation for CBT101 (autologous NK cell)
Approval of Clinical Trial Amendment: Change of Manufacturing Site for CBT101 (GMP Approval)
International recognition of CBC-GMP factory as an overseas manufacturing site
The 1st Plant (CBC-GMP) granted additional recognition as an overseas manufacturing facility
Export license secured for adipose-derived stem cells(Japan’s Ministry of Health, Labor, and Welfare)

2019

Awarded “AA” technology evaluation rating by Korea Technology Finance Corporation
Venture company certification from Korea Technology Finance Corporation
Technology transfer to Astellas Institute for Regenerative Medicine (AIRM), generating KRW 54.2 billion in technology commercialization
Establishment of Matica Biotechnology, Inc. for CDMO business in the U.S
The 1st Plant (CBC-GMP) granted recognition as an overseas manufacturing facility
Export license secured for activated autologous NK cells(Japan’s Ministry of Health, Labor, and Welfare)
Pharmaceutical manufacturing license from Korea’s Ministry of Food and Drug Safety
Acquisition of Singapore Medical Group (SMG), secured over 40 specialized clinics across three countries (CHA Healthcare)
Opening of an immuno-enhancement clinic at Bundang CHA Medical Center

2018

Establishment of Matica BioLabs (formerly CHA Bio Lab) through a physical division of basic research and CDMO business
Secured a site for the development of cell therapy products and the establishment of advanced manufacturing facilities(Pangyo’s 2nd Techno Valley)
Completed construction of CBC-GMP facility
Acquisition of CFC Global Pty Ltd in Australia, secured seven fertility clinics(CHA Healthcare)
Strategic partnership formed with Japan’s Oda Clinic through BioInsurance

2017

Completion of Phase 1/2a clinical trial for CordSTEM®-ST, an acute stroke therapy
Completion of Phase 2 clinical trial for PLX-PAD, a therapy for intermittent claudication

2016

IND approval for CordSTEM®-CD Kit Phase 1 clinical trial for knee cartilage defect treatment
Secured venture company certification from Korea Technology Finance Corporation

2015

Completion of Phase 1 clinical trial for hESC-RPE (embryonic) therapy for Stargardt disease, the first in Korea

CHA Network

[Main Office] CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488

Affiliates

Global Healthcare

Business

CHA Biotech

History